Safety and Tolerability Assessment of Dostarlimab in Adults with Chronic Hepatitis B on Nucleos(t)ide Analogue Therapy

The primary objective of this study is to evaluate the **safety** and **tolerability** of dostarlimab in adult participants with **chronic Hepatitis B** infection who are undergoing treatment with nucleos(t)ide analogue (NA) therapy. This is clinically relevant as it aims to determine the potential of dostarlimab as a safe adjunctive treatment option for individuals with chronic Hepatitis B, a condition that can lead to serious liver complications if not effectively managed.

The clinical trial involves a total of **9 participants** diagnosed with **Chronic Hepatitis B**. The study population includes both male and female subjects, with an age range categorized as **3**, which typically corresponds to adults. Participants were selected without targeting any vulnerable populations. The general health status of the participants is not specified, nor are there any particular lifestyle considerations such as diet or physical activity mentioned. The sponsor has not provided detailed information regarding the principal inclusion or exclusion criteria for this trial.

The clinical trial is designed to evaluate the **safety** and tolerability of dostarlimab in adult participants with **chronic Hepatitis B** infection who are currently receiving nucleos(t)ide analogue treatment. This study is a Phase 3 trial, which will employ a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated duration of the trial is approximately 21 months, with recruitment anticipated to commence on November 8, 2024, and the study expected to conclude by August 8, 2026.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into treatment groups. Throughout the trial, regular follow-up visits will be scheduled to monitor the participants' health status, adherence to the treatment protocol, and any adverse events. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The trial will culminate in an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes of the treatment.

The expected length of participant involvement in the study is contingent upon the trial's timeline, with each participant expected to remain in the study until its conclusion unless specific conditions necessitate early termination. Such conditions may include the occurrence of significant adverse events, withdrawal of consent, or non-compliance with the study protocol. The trial's design and procedures are structured to ensure the collection of comprehensive and accurate data, contributing to the understanding of dostarlimab's safety profile in the target population.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on the administration of other medicinal products or their role in the trial.

Furthermore, the documentation lacks information on the **participant compliance monitoring** procedures, dosing schedules, and any additional relevant information about drug administration. The absence of these details limits the ability to provide a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 3 study, indicating a focus on confirming the effectiveness of the intervention in a larger patient population. The trial is scheduled to commence recruitment on November 8, 2024, with an estimated completion date of August 8, 2026. Efficacy assessments will be conducted at predetermined intervals throughout the trial duration, utilizing scientifically validated methods and instruments. The specific parameters or endpoints for evaluating efficacy, such as symptom improvement scores or biomarker levels, are not detailed in the available data. The analysis of collected data will adhere to rigorous statistical methodologies to ensure the reliability and validity of the findings. The trial's design and execution will follow established clinical research standards to accurately determine the intervention's efficacy.